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Introduction: Affective disorders, including major depressive disorder (MDD),
are among the most severely disabling mental disorders, and in many cases are
associated with poor treatment outcomes. From the emergence of the mono-
amine hypothesis of depression, the first-line treatment for MDD had mainly
acted by inhibiting monoamine reuptake, and thereby increasing these levels
in the synaptic cleft. However, in recent years, several new antidepressant drugs
have appeared, including duloxetine, a dual serotonin (5-HT) andnoradrenaline
(NA) reuptake inhibitor recommended for the treatment of MDD.
Areas covered: The article reviews and discusses the biochemical and functional
profile of duloxetine splitting the review into acute and long-term treatment
with this dual monoamine reuptake inhibitor. In addition, the authors summa-
rize available preclinical behavioral research data, which have demonstrated
among other effects, the antidepressant-like activity of duloxetine in several
animal models. The authors focus on the most recent literature on synaptic
neuroplasticity modulation of this antidepressant drug. Finally, the authors
briefly mention other approved indications of duloxetine.
Expert opinion: Duloxetine inhibits 5-HT and NA reuptake, effectively desen-
sitizes various autoreceptors and promotes neuroplasticity. Clinically, duloxe-
tine is an effective antidepressant that is well tolerated and has significant
efficacy in the treatment of MDD.
Keywords: depression, dual-action antidepressant, duloxetine, noradrenaline, serotonin
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1. Introduction
Affective disorders, which include major depressive disorder (MDD), are among the
most prevalent forms of mental illness and it is estimated that 15% of the popula-
tion will suffer a depressive episode at some point in their lifetime [1,2]. According to
the World Health Organization, depression is one of the top 10 causes of morbidity
and mortality worldwide, and it is expected to be the second most common cause of
disability by 2020 [3]. Given the high prevalence of this disorder, its frequently
chronic nature and the associated risk of suicide, the development of new therapeu-
tic strategies to treat this condition is paramount.
Antidepressant treatments were first introduced in the 1950s, and the first drugs
used to treat depression were tricyclic antidepressants (TCAs) and monoamine oxi-
dase inhibitors (MAOI). The monoamine hypothesis of depression [4] was introduced
in the following decade, which maintained that deficits in brain serotonin (5-HT) and
noradrenaline (NA) gave rise to depression. Accordingly, in the 1970s and 1980s neu-
ropsychopharmacology focused on the development of drugs that selectively increased
the levels of these monoamines. These drugs, now known as selective serotonin
reuptake inhibitors (SSRIs) and noradrenaline reuptake inhibitors (NRIs), inhibit
the uptake of catecholamines and promote their bioavailability at the synaptic cleft.
Subsequent attempts to develop new antidepressant compounds that enhance
10.1517/17460441.2012.693912 © 2012 Informa UK, Ltd. ISSN 1746-0441 1
All rights reserved: reproduction in whole or in part not permitted
Ex
pe
rt 
O
pi
n.
 D
ru
g 
D
isc
ov
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
CA
 U
ni
ve
ris
ty
 o
f C
ad
iz
 o
n 
06
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
monoaminergic (i.e., both serotoninergic and noradrenergic)
neurotransmission led to the synthesis of dual monoamine
reuptake inhibitors, such as duloxetine.
Duloxetine was created by researchers at Eli Lilly and it
was first described in its racemic form (LY227942) in 1988.
Subsequently, the most potent enantiomer (LY248686 or
duloxetine) [5] was approved by the US Food and Drugs
Administration (FDA) for the treatment of major depression.
2. Duloxetine: biochemical and functional
profile
Duloxetine (LY248686, N-methyl-g-1-napthalenyloxy-2-
thiophene propanamine hydrochloride: Figure 1) is a dual
inhibitor of 5-HT and NA reuptake. The binding profile of
duloxetine in rat cortical synaptosomes demonstrates its inhibi-
tion of the 5-HT transporter (SERT) and NA transporter
(NET), with Ki values of 0.5 and 3.6, respectively [6,7]. These
values are in agreement with the results of ex vivo binding
assays performed in hippocampal and cortical slices [6,8].
Duloxetine thus inhibits 5-HT transport with greater potency
than NA transport (Table 1), with little or no affinity for other
neuronal receptors [9].
Duloxetine inhibits 5-HT and NA uptake in hypothalamic
and cortical synaptosomes, as evident through in vitro uptake
assays [7,10,11], with only a weak effect on dopamine (DA)
uptake in striatal synaptosomes [7] (Table 1). In ex vivo uptake
assays, acute duloxetine treatment inhibits both 5-HT and
NA reuptake in the rat hippocampus and hypothalamus [7,8].
In fact, duloxetine presents a higher affinity for both
5-HT and NA transporters than TCAs [12]. In addition,
duloxetine has a low selectivity ratio for NA/5-HT reuptake
inhibition [6]. Thus, compared with venlafaxine, as other
dual antidepressant, duloxetine is the most balanced dual
transporter inhibitor (Table 1) [6,12].
2.1 Acute duloxetine treatment
In rat microdialysis studies, acute duloxetine increases 5-HT,
NA and DA levels in the cerebral cortex [13-17], 5-HT and NA
levels in the hippocampus [11,18] and DA levels in nucleus
accumbens [15] in a dose-dependent manner. The nucleus
accumbens plays a critical role in the reward pathway and is
implicated in the pathophysiology of depression [19,20]. The
increase in DA levels in this region may reflect the affinity
of duloxetine for the DA transporter, although very high
concentrations of duloxetine are required to inhibit DA
uptake. Thus, the increases in DA observed are more likely
an indirect effect of the increases in 5-HT and NA levels.
Indeed, increased DA has been reported in the prefrontal
cortex following NRI treatment [21,22].
By inhibiting 5-HT and NA reuptake, duloxetine reverses the
depletion of 5-HT induced by p-CA ((±) para-chloroamphet-
amine) and the depletion of NA by 6-OHDA (6-hydroxydop-
amine hydrobromide) or a-MMT (a-methyl-m-tyrosine)
administration [6,16,23,24] in a dose-dependent manner. Interest-
ingly, duloxetine reversesMPTP (1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine)-induced NA depletion in the cerebral cortex
but not the striatum [23], further supporting the view that DA
levels are modulated indirectly by duloxetine-induced increases
in 5-HT and NA levels.
In several brain regions implicated in the therapeutic effect
of antidepressants, duloxetine reduces the 5-HT turnover rate.
This is determined by measuring the ratio of 5-HT to its prin-
cipal metabolite (5-hydroxyindoleacetic acid (5-HIAA)),
which has been correlated with an increase in 5-HT release
into synaptic clefts [23,25].
The effects of duloxetine have been analyzed when
administered in combination with ligands of autoreceptors
that modulate serotonergic and noradrenergic activity.
5-HT1A autoreceptors and a2-adrenoreceptors negatively
regulate the release of 5-HT and NA in serotenergic
and noradrenergic neurons, respectively. Antagonism of
5-HT1A with WAY100,635 or LY206130 potentiates the
duloxetine-induced increase in 5-HT but not that of NA
or DA in the rat frontal cortex and hypothalamus [17,26].
By contrast, co-administration of the 5-HT1A agonist bus-
pirone decreases cortical 5-HT levels, while augmenting
the NA and DA in this structure. These increases in NA
and DA may reflect the antagonistic properties of buspir-
one at inhibitory autoreceptors in the noradrenergic and
dopaminergic systems [27]. In the presence of duloxetine,
the a2-adrenoceptor antagonists atipamezole and I-PP
(1-(2-pyrimidyl)piperazine) potentiate the accumulation
of 5-HT, NA and DA in the rat frontal cortex [14].
By contrast, the effects of duloxetine are unaltered by the
b-adrenergic antagonist metoprolol [26].
In summary, acute duloxetine administration in rats induces a
general increase in catecholamine levels, and it reverses pharmaco-
logical depletion of 5-HT and NA. Moreover, the 5-HT1A
autoreceptor and the a2-adrenoreceptor play essential roles in
the mode of action of duloxetine.
Article highlights.
. There is an urgent need for new compounds to treat
major depressive disorder (MDD).
. Duloxetine is a dual serotonin (5-HT) and noradrenaline
(NA) reuptake inhibitor, with high affinity for 5-HT
transporter (SERT) and NA transporter (NET), and weak
affinity for the dopamine (DA) transporter.
. Chronic duloxetine treatment induces adaptive changes
in the 5-HT and NA systems, including
autoreceptor desensitization.
. Animal behavioral studies have demonstrated the
antidepressant- and anxiolytic-like effects of duloxetine,
in the absence of cognitive impairment.
. Duloxetine modulates neuronal plasticity by enhancing
the expression of neurotrophic factors such as
brain-derived neurotropic factor (BDNF).
. Duloxetine alleviates the physical symptoms of
depression, including aches and pains.
This box summarizes key points contained in the article.
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2.2 Long-term duloxetine treatment
Chronic duloxetine treatment exerts a long-term modulatory
effect on serotoninergic and noradrenergic systems. In vivo
microdialysis studies revealed that chronic duloxetine treatment
has no effect on basal levels of 5-HT, NA or DA in the rat
frontal cortex [15]. Accordingly, chronic treatment with SSRIs
or NRIs fails to modify 5-HT and NA levels, respectively [28,29].
These findings suggest that, the mode of action of duloxetine
when administered chronically involves adaptive changes that
alter autoreceptor function, as previously described following
long-term SSRI treatment [30-32].
In ex vivo uptake and binding studies in rodents, chronic
duloxetine treatment reduces the density of functional SERT
in the cortex [6,33-35], although no increase in 5-HT release is
produced in this brain region [34]. Strikingly, although 5-HT
transport is deregulated in the cortex, chronic duloxetine
treatment does not increase the release of this monoamine.
However, several studies have described increased 5-HT
release in response to the SERT down-regulation that follows
chronic SSRI treatment [36-38]. This discrepancy between the
effects of chronic duloxetine and SSRI regimens remains
unexplained, although it is possible that the noradrenergic
effects of duloxetine underlie these differences. Alternatively,
the increases in NA observed in the cortex may be directly
due to a reduction in the functional NET induced by dulox-
etine in this brain area [6,34]. Further research will be necessary
to elucidate the mechanisms that underlie this effect.
In ex vivo uptake assays, chronic duloxetine treatment aug-
ments 5-HT release in the hippocampus following, although it
has no effect on the density of functional SERT [34]. In vivo extra-
cellular recordings of CA3 hippocampal neurons have demon-
strated that the recovery time of the firing activity of these
neurons following microiontophoretic 5-HT administration is
similar after acute and chronic duloxetine treatment [8,39]. The
recovery time provides a measure of the in vivo activity of mono-
amine reuptake systems [38,40] and thus, these results suggest that
chronic duloxetine does not modify SERT function. Moreover,
duloxetine has no effect on the inhibitory firing rate of hippocam-
pal neurons, a parameter that reflects postsynaptic receptor
sensitivity [41]. This finding indicates that chronic duloxetine
treatment does notmodify postsynaptic receptors in hippocampal
neurons [39]. However, when a lower dose of duloxetine was used
a decrease in SERTdensity was observed [33]. The different dulox-
etine doses used in various studies may explain the variations in
the observed adaptive changes.
Following chronic duloxetine administration in rats, no alter-
ations in functional SERT density were observed in the hippo-
campus, nor was 5-HT1B autoreceptor sensitivity altered in
serotoninergic neurons [34], even though these autoreceptors
are desensitized by chronic SSRI treatment [42]. One explanation
for these different effects is the dual nature of duloxetine reup-
take inhibition, which may desensitize a2-heteroreceptors in
5-HT terminals [34], as previously described following chronic
NRI and MAOI treatment [36,43].
The dorsal raphe nucleus and locus coeruleus are key brain
regions involved in the modulation of serotoninergic and nor-
adrenergic transmission, respectively, each of which emits
projections to a wide array of structures, including the cortex
and hippocampus. Chronic SSRI treatment augments 5-HT
release and desensitizes SERT in the dorsal raphe [38] and
while duloxetine also enhances 5-HT release in this region,
it has no effect on SERT activity in ex vivo uptake assays [34].
Altered presynaptic receptor function most probably explains
these increases in 5-HT release and indeed, desensitization
of somatodendritic 5-HT1A and 5-HT1D autoreceptors was
described following chronic duloxetine treatment [34], which
O
NH • HCI
S
CH3
Duloxetine HCI
Figure 1. Chemical structure of duloxetine hydrochloride.
Table 1. In vitro binding affinity of duloxetine for
5-HT, NA and DA transporters, and for the inhibition of
catecholamine reuptake and antidepressants in vitro
binding affinity for 5-HT and NA human transporters.
Binding affinity and inhibition uptake Ki (nM)
[3H]-Paroxetine in vitro binding [7] 0.5 ± 0.1
[3H]-Nisoxetine in vitro binding [6] 3.6 ± 0.3
[3H]-5-HT uptake in cortical snps [7] 4.6 ± 1.1
[3H]-NA uptake in hypothalamic snps [7] 15.6 ± 2.9
[3H]-DA uptake in striatal snps [7] 369.2 ± 38.1
[3H]-5-HT uptake in whole brain snps [11] 1.9
[3H]-NA uptake in cortical snps [11] 3.1
Human antidepressants profile SERT NET
Duloxetine [6] 0.80 ± 0.04 7.50 ± 0.30
Venlafaxine [12] 8.90 ± 0.30 1060 ± 40
Amitriptyline [12] 4.30 ± 0.12 35 ± 2
Nortriptyline [12] 18 ± 1 4.37 ± 0.07
Imipramine [12] 1.40 ± 0.03 37 ± 2
Fluoxetine [12] 0.81 ± 0.02 240 ± 10
Citalopram [12] 1.16 ± 0.01 4070 ± 80
Paroxetine [12] 0.13 ± 0.01 40 ± 2
Sertraline [12] 0.29 ± 0.01 420 ± 20
Mirtazapine [12] >100000 4600 ± 300
Ki: Mean of affinity constants expressed in nM ± S.E.M. (Standard error of the
mean); 5-HT: Serotonin; NA: Noradrenaline; DA: Dopamine; snps:
Synaptosomes; NET: Noradrenaline transporter; SERT: Serotonin transporter.
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in turn may negatively regulate 5-HT release [44]. Extracellular
recordings from dorsal raphe neurons revealed a dose-
dependent inhibition of the firing of these neurons following
acute duloxetine administration [8,39,45], an effect that does
not persist when this drug is received chronically [39]. Given
that somatodendritic 5-HT1A autoreceptors negatively con-
trol the spontaneous firing rate of dorsal raphe neurons [44],
desensitization of these receptors following long-term duloxe-
tine treatment may underlie the restoration of basal firing
rates [39].
Chronic duloxetine treatment increases NA release in the
hippocampus, while having no effect on the density or function
of the NET or the b1-noradrenergic receptor [6,34]. This increase
in NA is a result of the desensitization of a2-heteroreceptors
in NA terminals [34,39], consistent with the desensitization of
a2-heteroreceptors observed after chronic NRI treatment [43,46].
In vivo extracellular recordings in CA3 hippocampal neurons
have revealed that both acute and chronic duloxetine administra-
tion enhances the recovery time of the firing activity of these
neurons following microiontophoretic NA administration [8,39],
suggesting that chronic duloxetine does not modify NA trans-
port. In addition, duloxetine has no effect on the inhibitory
firing rate of hippocampal neurons, indicating that the sensitivity
of postsynaptic receptors remains unaltered [39,41].
Based on the desensitization of a2-heteroreceptors in NA
terminals observed, the function of somatodendritic a2-autor-
eceptors was evaluated through in vivo electrophysiological
recordings of locus coeruleus neurons. Acute duloxetine
inhibited the spontaneous electrical activity of these neurons
in a dose-dependent manner [8], an effect that was reversed
by the a2-adrenoceptor antagonist idazoxan. These findings
demonstrate that somatodendritic a2-autoreceptors are not
desensitized by duloxetine.
In summary, chronic duloxetine treatment has no effect on
basal 5-HT, NA or DA levels in the cerebral cortex, although
it enhances NA but not 5-HT release, and it induces SERT
and NET dysfunction. In the hippocampus, chronic duloxe-
tine augments 5-HT and NA release, yet it has no effect
on SERT and NET density, while desensitizing terminal
a2-heteroreceptors but not 5-HT1B receptors. In the dorsal
raphe nucleus, chronic duloxetine augments 5-HT release but
it does not affect SERT density, while it desensitizes somato-
dendritic 5-HT1A and 5-HT1D autoreceptors. Finally, several
studies have described crosstalk between the serotonergic
and noradrenergic systems [8,47], which may have important
implications for the mode of action of duloxetine.
3. Behavioral studies
Several preclinical studies of behavior also evaluated
the biochemical and functional profile of duloxetine,
analyzing its effects on locomotor activity, body weight,
food intake, corporal temperature, ptosis, tremor, memory
and sleep, in addition to its antidepressant and anxiolytic
effects (Table 2).
In rodents, duloxetine treatment reduces food intake [48,49],
while chronic treatment in high doses leads to a decrease
in body weight [48,50], consistent with the decreased body
weight reported in duloxetine-treated patients [51]. Duloxetine
also reduces the body temperature [52], although it alle-
viates the hypothermia induced by reserpine, 8-OHDPAT
(8-hydroxyl-2-(di-n-propylamino)tetralin and mCPP (m-chloro-
phenyl piperazine) [35,52]. Moreover, duloxetine reverses
tetrabenazine-induced ptosis in a dose-dependent manner [52].
Duloxetine partially antagonizes oxotremorine-induced tremor
in mice, although it provokes a dose-dependent increase in head
movements and the tremor score induced by a precursor of
5-HT. In rats, this latter combination produced an increase in
head movement but not in tremor [52].
Sleep abnormalities are one of the primary symptoms of major
depressive disorder (Diagnostic and Statistical Manual IV Text
Revision, DSMIV-TR) [20,53] and accordingly, several studies
have analyzed the effect of duloxetine on sleep using rat electroen-
cephalogram (EEG) recordings. A decrease in rapid eye move-
ment (REM) and slow-wave deep sleep was reported following
acute duloxetine treatment, along with a parallel increase in the
awake period [52]. However, no such effects of duloxetine on
REM and slow-wave deep sleep were observed in a subsequent
study, despite the decreased paradoxical sleep and increased awake
period produced [11]. The discrepancies between these studies
may be explained by the different duloxetine doses employed.
Notably, significant disruption of sleep architecture has been
demonstrated following NRI and dual-action antidepressant
treatment [11], suggesting that the noradrenergic properties of
duloxetine may underlie its effects on sleep.
The antidepressant-like activity of duloxetine has been
measured in the forced swimming test (FST), a commonly
used test in which reduced immobility time is correlated with
antidepressant activity [54,55]. Acute and subacute duloxetine
treatment decreased the immobility time in the FST in most
studies [52,56-60]. However, when a lower dose was used no such
decrease in immobility time was observed after acute duloxetine
administration, yet antidepressant-like effects were observed
when duloxetine was co-administered with a 5-HT1A antagonist
(WAY100,635) [17]. The antidepressant-like effects of duloxetine
were also enhanced when it was administered in combination
with an AMPA receptor potentiator (LY392098) [58]. Moreover,
duloxetine also induces antidepressant-like effects in the mouse
tail suspension test (TST) [61]. As predictive tests of antidepressant
activity measure active animal behavior, it is crucial to evaluate
spontaneous locomotor activity to ensure the results are correctly
interpreted and to avoid false positives. At the higher end of
the dose range used in preclinical studies, antidepressants decrease
spontaneous locomotor activity [60]. Similarly, higher subacute
doses of duloxetine decrease locomotor activity [60], while
acute and chronic treatment with lower doses has no such
effect [24,35,62-64]. Importantly, no increase in locomotor activity
has been reported following duloxetine administration at any
dose, indicating that the observed effects in FST and TST are
not due to the induction of hyperactivity.
S. Torres-Sanchez et al.
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Table 2. Published studies of duloxetine for preclinical behavioral tests.
Duloxetine dose Effect
Body weight (rat) Chronic; 100 mg/kg p.o. (14 days) #Body weight [50]
Chronic, 30 mg/kg p.o. (4 weeks) $ Body weight [48]
Food intake (rat) Acute; 30 mg/kg p.o. # Food intake [49]
Chronic, 30 mg/kg p.o. (4 weeks) # Food intake [48]
Body temperature (mouse)
Reserpine-induced hypothermia Acute; 3.13 -- 12.5 mg/kg p.o. # Hypothermia [35,52]
8-OHDPAT-induced hypothermia Chronic; 10 mg/kg p.o. (twice daily, 28 days)
mCPP-induced hypothermia Chronic; 10 mg/kg p.o. (twice daily, 28 days)
Ptosis
Tetrabenazine-induced ptosis (mouse) Acute; 3.13 -- 25 mg/kg p.o. # Ptosis (dose-dependent) [52]
Tetrabenazine-induced ptosis (rat) Acute; 12.5 -- 50 mg/kg p.o.
Tremor
5-HTP-induced tremor (mouse) Acute; 25 -- 100 mg/kg p.o. "Tremor score (dose-dependent) [52]
5-HTP-induced tremor (rat) Acute; 12.5 -- 25 mg/kg p.o. $ Tremor score [52]
Oxotremorine-induced tremor (mouse) Acute; 25 -- 50 mg/kg p.o. # Tremor score [52]
Lacrimation and salivation (mouse)
Oxotremorine-induced lacrimation and salivation Acute; 3.13 -- 200 mg/kg p.o. $ Salivation or lacrimation [52]
Locomotor activity
Spontaneous locomotor activity (mouse) Acute; 1 -- 30 mg/kg i.p. $ Locomotor activity [35,63,64]
Chronic; 10 mg/kg p.o. (twice daily, 28 days)
Chronic; 2 -- 18 mg/kg s.c. (28 days)
Spontaneous locomotor activity (rat) Subacute; 40 mg/kg s.c. # Locomotor activity [60]
Rotarod (rat) Acute; 3 -- 30 mg/kg i.p. $ Time on rotarod [24,62]
5-HTP-induced head movement (mouse) Acute; 12.5 -- 100 mg/kg p.o. "Head movements
(dose-dependent) [52]5-HTP-induced head movement (rat) Acute; 12.5 -- 25 mg/kg p.o.
Antidepressant activity
Forced swimming test (mouse) Acute; 4 -- 32 mg/kg i.p. # Immobility time [52,56-58]
Acute; 2.5 mg/kg i.p. + LY392098
Subacute; 25 -- 100 mg/kg p.o.
Forced swimming test (rat) Acute; 5 mg/kg s.c. $ Immobility time [17]
Acute; 5 mg/kg s.c. + WAY100,635 # Immobility time [17,59,60]
Subacute; 10 -- 40 mg/kg s.c.
Subacute; 40 mg/kg i.p.
Tail suspension test (mouse) Acute; 5 -- 40 mg/kg i.p. # Immobility time [61]
Anxiety (mice)
Open field (mouse) Chronic; 6 -- 18 mg/kg s.c. (28 days) # Time spent in center area [63]
Zero maze (mouse) Acute; 3 -- 30 mg/kg i.p. $ Time spent in open area [35]
Chronic; 10 mg/kg p.o. (twice daily, 28 days) "Time spent in open area [35,64]
Stress-induced ultrasonic vocalization (rat) Acute; 20 -- 40 mg/kg i.p. # USV duration (dose-dependent) [66]
Exploratory behavior in novel environment
(mouse)
Acute; 2 -- 40 mg/kg s.c. "Locomotor activity [65]
5-HTTP: 5-hydroxytryptophan; 8-OHDPAT: (8-hydroxyl-2-(di-n-propylamino)tetralin; EEG: Electroencephalogram; i.p.: Intraperitoneally; mCPP: (m-chlorophenyl
piperazine); p.o.: By oral gavage; REM: Rapid eye movement; s.c.: Subcutaneously.
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Anxiolytic effects of chronic duloxetine have been reported,
as evident through an increase in the time spent in the open
area in the zero maze test [35,64]. However, a decrease in the
time spent in the central area in the open field test was
also reported elsewhere, suggesting an anxiogenic effect [63].
Duloxetine also increases exploratory behavior in a novel
environment [65] and it provokes a dose-dependent reduction
in stress-induced ultrasonic vocalization [66], indicative of an
anxiolytic-like effect.
No effects of duloxetine on short- or long-term memory
have been reported in the rat inhibitory avoidance task [67].More-
over, memory impairment induced by MK-801, an NMDA
antagonist, is unaltered by duloxetine, that is, it is unable
to recover the impairment onmemory produced by this glutama-
tergic antagonist [67]. In summary, the effects of duloxetine
most closely linked with depression are a reduction in body
weight, food intake and, at higher doses, locomotor activity.
Antidepressant-like effects of duloxetine have been demonstrated
in rodents in the FST and TST, and anxiolytic-like effects in the
zero maze.
4. Duloxetine and synaptic plasticity
In recent years, several findings have indicated the importance of
neurotrophins and neuronal plasticity in mood regulation and
antidepressant-like effects. The delay between the rapid increase
in monoamine levels induced by antidepressants and the onset
of clinical effects suggests that the antidepressant mode of action
involves gradual alterations in synaptic plasticity. The neurotro-
phic hypothesis of depression postulates that low levels of neuro-
trophins underlie depression [68,69]. Neurotrophins are growth
factors that are essential for the neuronal adaptations that mediate
different aspects of mood regulation [68,70].
Several studies have investigated the effects of duloxetine on
neurotrophin levels and neuronal plasticity. Chronic, but not
acute duloxetine treatment increases the expression of the
mature form of brain-derived neurotropic factor (BDNF) in
both the cortex and hippocampus [50,71-73], and while the pre-
cursor form of BDNF (pro-BDNF) preferentially promotes
programmed neuronal death, the mature form enhances neu-
ronal survival and differentiation. Several other antidepressant
drugs also augment BDNF, including those SSRIs and
NRIs [74,75], implicating the upregulation of BDNF in the
adaptive changes induced by antidepressants. Indeed, antide-
pressant treatment reverses the reduction in serum BDNF lev-
els observed in depressed patients [76].
Arc (activity-regulated cytoskeleton-associated protein) is a
growth factor and an immediate early gene that plays a funda-
mental role in neural plasticity, which has also been impli-
cated in the modulation of mood [77,78]. An increase in Arc
expression in rat cortex and midbrain after chronic duloxetine
treatment [73] and in addition, a strong correlation between
Arc and BDNF expression was observed in the cortex and
midbrain after chronic but not acute duloxetine treatment.
In the only study to investigate the effect of duloxetine on
adult hippocampal neurogenesis, no changes were detected
in cell survival or in the number of newly born cells in the
dentate gyrus of the hippocampus.
Thus, together these findings indicate that adaptive changes
in neuronal plasticity induced by duloxetine contribute to its
therapeutic effect in the treatment of depression.
5. Other uses of duloxetine
Both 5-HT and NA monoamines modulate ascending spinal
nociceptive neurotransmission via the descending inhibitory
pain pathway [79,80]. Accordingly, although developed to man-
age depression, duloxetine may also produce analgesia in con-
ditions of chronic pain [62,81-83] and indeed, it has been
approved for the treatment of diabetic neuropathic pain [84].
Table 2. Published studies of duloxetine for preclinical behavioral tests (continued).
Duloxetine dose Effect
Memory (rat)
Inhibitory avoidance task Acute; 10 -- 20 mg/kg i.p. $ Short- or long-term memory [67]
Subacute; 10 -- 20 mg/kg i.p. (5 days)
Acute; 10 -- 20 mg/kg i.p. + MK-801
Sleep (rat)
Sleep EEG recording Acute; 12.5 -- 25 mg/kg p.o. # REM sleep [52]
# Slow-wave deep sleep [52]
"Awake period [52]
Acute; 7.7 mg/kg i.p. $ REM sleep [11]
$ Slow-wave deep sleep [11]
"Awake period [11]
# Paradoxical sleep [11]
5-HTTP: 5-hydroxytryptophan; 8-OHDPAT: (8-hydroxyl-2-(di-n-propylamino)tetralin; EEG: Electroencephalogram; i.p.: Intraperitoneally; mCPP: (m-chlorophenyl
piperazine); p.o.: By oral gavage; REM: Rapid eye movement; s.c.: Subcutaneously.
S. Torres-Sanchez et al.
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Duloxetine is also effective in treating stress urinary inconti-
nence due to the inhibition of 5-HT and NA reuptake
induced in specific spinal cord motor neurons that innervate
the striated muscle of the urethral sphincter [85,86].
6. Conclusion
Duloxetine belongs to a new group of antidepressants that
selectively inhibit the reuptake of monoamines, particularly
5-HT and NA, showing little affinity for other receptors. As
well as inhibiting the reuptake of monoamines, traditional
TCAs have a high affinity for other receptors types, resulting
in unwanted side effects. Recent findings have also demon-
strated that duloxetine modulates the expression of neuro-
trophic factors, such as BDNF, which has important
implications for our understanding of the etiology and evolu-
tion of depression, indicating that the basis of depression is
more complex than simple monoamine deficit. Preclinical
studies of novel drugs like duloxetine, which combine the
blockage of monoamine reuptake with the modulation of neu-
roplasticity, provide significant insights into possible future
approaches to treat depression. In addition, such studies high-
light the potential of other similar compounds to treat disor-
ders such as pain and cognitive decline, which are frequently
associated with depression.
7. Expert opinion
Depression is one of the most prevalent mental disorders and
it often represents a chronic condition. Furthermore, a large
proportion of depressed patients respond poorly to the thera-
pies currently available, underlining the need for new and
innovative antidepressant drugs that are designed on the basis
of our understanding of the molecular and biochemical
processes that underlie this condition.
While several substrates have been implicated in the etiol-
ogy of depression in recent years, the vast majority of the
new antidepressants still target 5-HT and NA transmission.
Duloxetine, a 5-HT and NA reuptake inhibitor, was intro-
duced to the market some years ago, and has since proved
an effective and well-tolerated antidepressant. Duloxetine
inhibits 5-HT and NA reuptake both in vitro and in vivo,
with greater affinity for the 5-HT than the NA transporter,
and minimal effects on dopaminergic transmission. In this
way, duloxetine presents low constant affinities for both
monoamines transporters. However, compared with TCAs,
duloxetine lacks relevant effects on neurotransmitter recep-
tors, which conferred it the avoidance of the typical TCAs
side effects. Additionally, duloxetine has a potential metabo-
lite which would retain the ability for the inhibition of the
reuptake of both monoamines.
Inmicrodialysis studies, acute duloxetine increases 5-HT,NA
andDA in the rat cerebral cortex in a dose-dependentmanner, as
well as 5-HT and NA in the hippocampus and DA in nucleus
accumbens. These findings demonstrate that duloxetine can
modulate all three monoamines implicated in the symptoms of
depression. By contrast, chronic duloxetine treatment has
a significant effect on the autoregulation of NA and 5-HT
release, altering the sensitivity of 5-HT1A autoreceptors and
a2-adrenoreceptors. These two autoreceptors are involved in
monoamine release in terminal areas, which in turn modulates
NA and 5-HT. Thus, desensitization of these autoreceptors
accelerates the onset of any antidepressant effects.
Duloxetine is effective in most behavioral tests used to
detect antidepressant-like activities. Moreover, this com-
pound exhibits anxiolytic-like activity in several behavioral
tests of anxiety in rodents, while displaying no effects on
memory. On the other hand, duloxetine reduced food intake
in rats showing low propensity to cause weigh gain, TCAs
typical side effect. Chronic duloxetine treatment increases
BDNF expression in the cortex and hippocampus, which is
strongly implicated in its antidepressant activity. Indeed, a
large body of evidence suggests that BDNF-mediated neuro-
plasticity plays a pivotal role in both the pathophysiology
and pharmacotherapy of depression.
Depression is characterized by a constellation of symptoms
presented by the majority of patients. In addition to the
so-called emotional symptoms, depressive patients may also
experience physical symptoms, such as aches and pains. Impor-
tantly, through the same mechanisms that underlie its antide-
pressant effects (i.e., inhibition of 5-HT and NA reuptake),
duloxetine exerts analgesic effects in several animal models of
pain as other analgesic antidepressant drugs. However, duloxe-
tine elicits its antidepressant and analgesic effects at the same
clinical doses. This property might be useful in the comorbidity
pain and depression condition or for treating physical painful
symptoms of depression.
Together, the findings reviewed here demonstrate that the
development and preclinical testing of duloxetine proves it
to be an effective antidepressant for the long-term treatment
of depressed patients.
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